New Delhi: The Drug Controller General of India (DCGI) has granted approval to Dr Reddy`s, a global pharmaceutical company headquartered in India, to conduct phase 2 and 3 clinical human trials of the Sputnik V, a coronavirus vaccine made by Russia.
Co-chairman and Managing Director of Dr Reddy`s Laboratories G.V. Prasad in a statement said “This is a significant development that allows us to commence the clinical trials in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic.”
“On regulatory approval in India, RDIF shall supply to Dr Reddy`s 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic,” a statement from the Russian fund had earlier stated.
